Experimental CAR T-Cell therapy for leukemia shows early promise but study halted
NCT ID NCT05654779
First seen Feb 15, 2026 · Last updated May 12, 2026 · Updated 13 times
Summary
This early-phase study tested a new cell therapy (LCAR-AMDR cells) in 4 people with acute myeloid leukemia that had come back or not responded to standard treatments. The therapy uses specially engineered immune cells to target two proteins on leukemia cells. The study was terminated early, and its main goals were to check safety and find the right dose. Because lifelong medication may be needed, this is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Gobroad BoRen Hospital
Beijing, Beijing Municipality, 100070, China
-
Chinese Academy of Medical Science and Blood Disease Hospital
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.